Elan, Proteostasis Join Forces in Early Stage Collaboration
By Catherine Shaffer
Thursday, May 26, 2011
Elan Corp. has committed as much as $50 million in a new approach to neurodegenerative disease being pioneered by Cambridge, Mass.-based Proteostasis Therapeutics Inc. The alliance will make use of Proteostasis assets and expertise in protein folding to identify and advance molecular entities that prevent misfolding of protein.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.